Bedaquiline + Pretomanid + Moxifloxacin + Pyrazinamide
“BPaMZ” is a promising TB treatment regimen in development that has the potential to be an improved treatment for the majority of TB patients. The BPaMZ regimen consists of bedaquiline (B), pretomanid (also known as PA-824 or Pa), which are two of the newest and most promising drugs for tuberculosis (TB), and moxifloxacin (M) and pyrazinamide (Z), which are established drugs in the current treatment. BPaMZ shows promise to reduce TB treatment to as little as three months. This is an oral regimen, removing the need for injectables as part of MDR-TB treatment and also projecting to be markedly less expensive than current MDR-TB therapy.
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)\
- A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005)